Piramal Pharma Limited (PPLPHARMA.BO)
BSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹198.45 (+1.69%) as of
Key statistics
- Market cap
- 263.16B
- Forward P/E
- 48.86
- EPS (TTM)
- -2.37
- Dividend yield
- 0.00%
- 52-week range
- 132.50 – 231.85
- Beta
- 0.34
- Revenue (TTM)
- 92.05B
- Profit margin
- -3.41%
- Analyst target
- ₹236.45
- Volume
- 111.86k
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. In addition, the company operates as a contract development and manufacturing organization, providing process development, scale-up, and GMP manufacturing services for vaccines and biologics. The company was incorporated in 2020 and is based in Mumbai, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Mumbai, India
- Employees
- 7,120
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.